Literature DB >> 8731955

Analysis of plasma fibrinolysis in the patients with acute cerebral infarction.

Y D Shang1, X M Liu, Z Cai, M S Yang.   

Abstract

In the present study, the plasma fibrinolytic activity in 30 cases of cortical artery territory cerebral infarction (CACI) and 32 cases of perforating artery territory cerebral infarction (PACI) within 3 days after ictus, and 30 sex- and age-matched controls without cardio-cerebrovascular diseases were evaluated by a comprehensive panel of assay, including the plasma tPA activity, PAI activity, endothelial capacity of tPA release and PAI/tPA ratio. The results showed that the plasma fibrinolysis and the endothelial potential to release tPA responding to stimulation in both subtypes of the patients were significantly lower than those in the controls, which provide the theoretical basis for carrying out the thrombolytic therapy in the ischemic stroke. And the study also suggested that increased plasma PAI activity could increase the risk of AS thrombotic events with increased serum triglyceride level.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8731955     DOI: 10.1007/BF02887904

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  10 in total

1.  The plurality of subcortical infarction.

Authors:  J Bogousslavsky
Journal:  Stroke       Date:  1992-05       Impact factor: 7.914

Review 2.  Diagnosis and treatment of ischemic stroke.

Authors:  L R Caplan
Journal:  JAMA       Date:  1991-11-06       Impact factor: 56.272

Review 3.  Thrombolytic therapy in cerebrovascular disorders.

Authors:  S R Levine; T G Brott
Journal:  Prog Cardiovasc Dis       Date:  1992 Jan-Feb       Impact factor: 8.194

4.  Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity.

Authors:  S Dawson; A Hamsten; B Wiman; A Henney; S Humphries
Journal:  Arterioscler Thromb       Date:  1991 Jan-Feb

Review 5.  Coagulation abnormalities and cerebral infarction.

Authors:  M Greaves
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

6.  Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population.

Authors:  I B Sundell; T K Nilsson; G Hallmans; G Hellsten; G H Dahlén
Journal:  Atherosclerosis       Date:  1989-11       Impact factor: 5.162

7.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

8.  Hypertriglyceridemia and regulation of fibrinolytic activity.

Authors:  L Mussoni; L Mannucci; M Sirtori; M Camera; P Maderna; L Sironi; E Tremoli
Journal:  Arterioscler Thromb       Date:  1992-01

Review 9.  The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review.

Authors:  S Dawson; A Henney
Journal:  Atherosclerosis       Date:  1992-08       Impact factor: 5.162

10.  Impaired fibrinolysis in coronary artery disease.

Authors:  R B Francis; D Kawanishi; T Baruch; P Mahrer; S Rahimtoola; D I Feinstein
Journal:  Am Heart J       Date:  1988-04       Impact factor: 4.749

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.